US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

MXCT

MaxCyte (MXCT)

MaxCyte Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MXCT

1 2 3 4 5 6 7 8 9 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/03/21	07 : 49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
2025/03/21	07 : 47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
2025/03/21	07 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
2025/03/19	09 : 51	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
2025/03/19	09 : 49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
2025/03/19	09 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
2025/03/12	06 : 05	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:MXCT	MaxCyte Inc
2025/03/12	05 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MXCT	MaxCyte Inc
2025/03/12	05 : 05	GlobeNewswire Inc.	MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance	NASDAQ:MXCT	MaxCyte Inc
2025/02/14	08 : 17	Edgar (US Regulatory)	Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:MXCT	MaxCyte Inc
2025/02/12	16 : 00	GlobeNewswire Inc.	MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs	NASDAQ:MXCT	MaxCyte Inc
2025/02/07	16 : 00	GlobeNewswire Inc.	MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference	NASDAQ:MXCT	MaxCyte Inc
2025/01/30	21 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MXCT	MaxCyte Inc
2025/01/30	16 : 00	GlobeNewswire Inc.	MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments	NASDAQ:MXCT	MaxCyte Inc
2025/01/30	06 : 13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
2025/01/15	06 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
2025/01/13	21 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MXCT	MaxCyte Inc
2025/01/13	17 : 05	GlobeNewswire Inc.	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results	NASDAQ:MXCT	MaxCyte Inc
2024/12/31	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
2024/12/28	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MXCT	MaxCyte Inc
2024/12/27	06 : 16	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:MXCT	MaxCyte Inc
2024/12/23	16 : 00	GlobeNewswire Inc.	MaxCyte Announces Retirement of Board Member Art Mandell	NASDAQ:MXCT	MaxCyte Inc
2024/12/11	06 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
2024/12/09	22 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MXCT	MaxCyte Inc
2024/12/09	16 : 00	GlobeNewswire Inc.	MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance	NASDAQ:MXCT	MaxCyte Inc
2024/11/14	09 : 14	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:MXCT	MaxCyte Inc
2024/11/13	22 : 05	GlobeNewswire Inc.	MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics	NASDAQ:MXCT	MaxCyte Inc
2024/11/09	07 : 31	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:MXCT	MaxCyte Inc
2024/11/07	06 : 55	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MXCT	MaxCyte Inc
2024/11/07	06 : 22	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MXCT	MaxCyte Inc

Showing the most relevant articles for your search:NASDAQ:MXCT

1 2 3 4 5 6 7 8 9 次へ >>

Mayo Lake Minerals

Cyprus Tf 0,95% Ge32 Eur

Defiance Daily Target 2x...

Ireland Tf 2,4% Mg30 Eur

Cyprus Fx 3.25% Jun31 Eur

Ga.Ma Tf 4,75% Mg29 Amor...

Ggb Fb30 Sc Eur

WisdomTree International...

Cdp Tf 1,98% Mz28 Eur

Brera Tv Mg72 Abs Amort ...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約